InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
14%
T+90 mean return
-12.2%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Howell Kelli Mari, Vice-Président Exécutif, Stratégies Cliniques. Officer active across 1 company, notably Alphatec Holdings, Inc.. Cumulatively, 9 filings have been recorded. History available since 29 April 2021. The latest transaction was filed on 5 August 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations9 total
6,050 shares@ US$8.034.9% of flowCommon StockSEC:0001415889-22-008433:0
2,940 shares@ US$10.940.0025% mcap3.1% of flowCommon StockSEC:0001179110-22-002366:0
25,000 shares0Common StockSEC:0001179110-22-001694:0
6,050 shares@ US$15.230.0066% mcap8.5% of flowCommon StockSEC:0001179110-21-008020:0
6,050 shares@ US$15.238.0% of flowCommon StockSEC:0001179110-21-008020
17,525 shares@ US$14.8123.2% of flowCommon StockSEC:0001179110-21-005569
17,525 shares@ US$14.810.018% mcap23.2% of flowCommon StockSEC:0001179110-21-005569:0
11,474 shares@ US$16.3316.8% of flowCommon StockSEC:0001179110-21-004763
11,474 shares@ US$16.330.013% mcap16.8% of flowCommon StockSEC:0001179110-21-004763:0
9 of 9 declarations
About Howell Kelli Mari
Kelli Mari Howell is Executive Vice President, Clinical Strategies at Alphatec Holdings, Inc. She is responsible for leading clinical initiatives and product development strategy. Her expertise in healthcare and clinical operations management is essential to support the company's growth.
